Navigation Links
GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois
Date:7/25/2014

LAS VEGAS, July 25, 2014 /PRNewswire/ -- GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to announce the execution of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an Illinois limited liability company formed to pursue the acquisition of both cultivation and dispensary medical marijuana licenses in the state of Illinois. Pursuant to the MOU, GBLX will acquire a 20% equity interest in LaurelCo, LLC in exchange for licenses to use our proprietary GrowBLOXTM growing chambers, as well as all technology related to the machines and to various other proprietary technologies ("GrowBLOXTM Solutions") required for the cloning, growing, curing, and creation of pharmaceutical grade medical marijuana. Further, GBLX will provide technical assistance during the upcoming complex Illinois license application process. The MOU further provides that after LaurelCo, LLC has received one or more licenses in the state, GBLX will provide growing chambers for the LaurelCo, LLC's growing facilities, in exchange for an accelerated payback of actual costs, plus a 10% royalty interest going forward in any products created in the chambers and sold by the LaurelCo, LLC licensed entity.

Laurel Dineff, CEO and principal of LaurelCo, LLC said, "We are extremely excited about our new arrangement with GBLX. We have expended considerable resources in developing our plan for medical marijuana growth in this great state of Illinois. After exhaustive research, we have concluded that GBLX has not only the best growing technology, but also the best approach to making medical marijuana the serious pharmaceutical  it should be to treat the many maladies for which it has proven to be effective."

Craig Ellins, CEO of GBLX, stated, "We could not be more pleased to have this partnership with LaurelCo, LLC. The resources that its principals have made available to it, the prodigious quantity of good work that has already been done in terms of obtaining real property and other facilities necessary for the business, and the wonderful attitude of LaurelCo, LLC's management will make for a successful licensing effort and a prosperous and exemplary business. Moreover," he continued, "the agreement with LaurelCo, LLC represents a clear step forward in the GBLX strategy to create a nationwide supply of pharmaceutical grade and branded medical marijuana that is consistent and efficacious no matter where it is grown. With the formalization of our relationship with LaurelCo, LLC in Illinois, we are setting a standard for our growth into states in which GBLX does not have resources in place to operate a medical marijuana business by seeking out great partnerships who will operate the local business and be part of our nationwide plans."

About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation.  The GrowBLOXTM chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product.  The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions.  http://www.gbsciences.com

Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are inherently unreliable and actual results may differ materially.  Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105


'/>"/>
SOURCE GrowBLOX Sciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
3. KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
4. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
5. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
6. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
8. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
9. QPS Acquires JSW Life Sciences, Largest Independent Contract Research Organization in Austria
10. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
11. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... Ind. , Feb. 5, 2016  Zimmer Biomet ... pricing of the previously announced underwritten secondary offering of ... its stockholders, consisting of affiliates of Blackstone and Goldman ... at an initial price of $96.45 per share. The ... the offering.  Neither Zimmer Biomet nor any of its ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled ... provide the most effective tattoo removal today, Dr. Bentkover is the only doctor in ... Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) as ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
Breaking Medicine News(10 mins):